Navigation Links
Hard To Treat Diseases (HTDS) Delivers Varicella Vaccine To Guatemala
Date:9/22/2009

SHENZHEN, China, Sept. 22 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com The Company is pleased to announce the first batch delivery of the Varicella vaccine to Guatemala. Varicella-zoster virus (VZV) is a DNA virus of the herpesvirus family. VZV causes a primary illness (varicella or chickenpox) and establishes latency in the sensory nerve ganglia, which may be reactivated later as herpes zoster (shingles). VZV is spread by the airborne route as well as by direct contact with the virus shed from skin lesions. (source http://www.phac-aspc.gc.ca/im/vpd-mev/varicella-eng.php)

Mellow Hope management sees this delivery as a significant event. According to data and research available to the company, this newly penetrated Guatemalan market, of the Varicella Vaccine, marks the first batch of Varicella Vaccine produced in China, to enter the markets in Central America.

In other company news the company is continuing to compile a video of its offices and infrastructure in China and various videos on the H1N1 vaccine which are and will be posted shortly on its web site www.htdsmedical.com. The company will shortly be posting certain resolutions and amendments as filings on Pink Sheets which relate to the recent CUSIP change announcements and the positive strides the company has made in that regard.

More details to follow.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and Dr. Douglas ... not do their research and undergo cosmetic dermatology treatments from unqualified practitioners or worse, ... renaissance and every other month a new treatment or device is launched, promising everlasting ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... Mentz won "Best Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty ... France. , The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study has ... reproducibility and accuracy of placing precordial electrodes with little cognitive effort and a ... 60 years, studies have shown that single electrode misplacement is one of the ...
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)...  Results from the Phase II SUSTAIN study show ... the median annual rate of sickle cell-related pain crises ... p=0.010) in patients with or without hydroxyurea therapy 1 ... featured in the official press briefing at the 58 ... and presented during the Plenary Scientific Session tomorrow (Abstract ...
Breaking Medicine Technology: